Regulatory restrictions on animal use have increased the reliance of risk assessors and regulators on in vitro test systems. Ideally, tissue-based assays could replace the animal studies as follow-up tools to verify results from standard in vitro assays. The RSMN assay combines the EpiDerm™ 3D reconstructed...
Check out the recently released special issue of Applied In Vitro Toxicology: Application of In Vitro Toxicology Approaches for the Evaluation of Next-Generation Nicotine Products. The issue includes several articles by IIVS scientists and other experts. View the issue online....
Read the latest issue of our newsletter: IIVS at SOT 2017: Ancillary Meetings, posters, the IIVS booth; IIVS 20th Anniversary celebration on June 12, introducing our new website, update on our new respiratory toxicology lab, and much more. Read more....
Presented at the National Academies of Sciences, Engineering, and Medicine's (NAS) workshop on electronic nicotine delivery systems (ENDS), e-cigarettes....
The Alternatives Research & Development Foundation (ARDF), which promotes alternatives to the use of laboratory animals in research, testing, and education, is currently soliciting research proposals for its 2017 Alternatives Research Grant Program. ARDF is offering up to $40,000 to support individual projects. Preference will be...
ECHA’s updated guidance gives advice on how to use non-animal test methods, which are now the default for many endpoints. Registrants are encouraged to take the changes into account when deciding their testing strategies. Read more....
Presented at the 2nd Good Laboratory Practice Compliance Summit, January 26-27, 2017, Arlington, VA...
Amanda Ulrey, RQAP-GLP, IIVS Director of Quality & Compliance, will be presenting at the 2nd Good Laboratory Practice Compliance Summit and the SQA Annual Meeting & Quality College. Jan. 26-27, 2018: 2nd Good Laboratory Practice Compliance Summit “Case Study: Applying GLPs to New, Non-Animal Assays” Mar. 26-31: SQA...
The personal care industry is focused on developing safe, more efficacious, and increasingly milder products, that are routinely undergoing preclinical and clinical testing before becoming available for consumer use on skin. In vitro systems based on skin reconstructed equivalents are now established for the preclinical...